A Multicenter, Uncontrolled, Open-label, Dose-titration Trial to Investigate the Efficacy and Safety of Tolvaptan Tablets in Patients With Hyponatremia in Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)
Latest Information Update: 07 Dec 2021
Price :
$35 *
At a glance
- Drugs Tolvaptan (Primary)
- Indications Hyponatraemia
- Focus Therapeutic Use
- Sponsors Otsuka Pharmaceutical
- 19 Sep 2019 Status changed from recruiting to completed.
- 09 Feb 2017 New trial record